Cargando…
Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
BACKGROUND: Lenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and to identify factors associated with decreased lenvatinib adherence. MET...
Autores principales: | Tateai, Yoshikazu, Kawakami, Kazuyoshi, Teramae, Minori, Fukuda, Naoki, Yokokawa, Takashi, Kobayashi, Kazuo, Shibata, Naoki, Suzuki, Wataru, Shimizu, Hisanori, Takahashi, Shunji, Ozaka, Masato, Sasahira, Naoki, Hori, Satoko, Yamaguchi, Masakazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653419/ https://www.ncbi.nlm.nih.gov/pubmed/37972015 http://dx.doi.org/10.1371/journal.pone.0294320 |
Ejemplares similares
-
Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy
por: Ito, Genta, et al.
Publicado: (2021) -
Chemotherapy for Biliary Tract Cancer in 2021
por: Sasaki, Takashi, et al.
Publicado: (2021) -
Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis
por: Uesato, Yasunori, et al.
Publicado: (2020) -
Successful removal of a biliary metal stent using the stent-in-stent-in-stent technique
por: Matsuyama, Masato, et al.
Publicado: (2023) -
Prospective study of EUS-guided tissue acquisition with a 20G core biopsy needle with a forward bevel for solid pancreatic mass
por: Kanata, Ryo, et al.
Publicado: (2021)